miR‑493 inhibits proliferation and invasion in pancreatic cancer cells and inversely regulated hERG1 expression

Zhi,Duo; Zhao,Xin; Dong,Mei; Yan,Caichuan

doi:10.3892/ol.2017.7178

miR‑493 inhibits proliferation and invasion in pancreatic cancer cells and inversely regulated hERG1 expression

Authors:
- Duo Zhi
- Xin Zhao
- Mei Dong
- Caichuan Yan
View Affiliations

Affiliations: Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang 150040, P.R. China, Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang 150081, P.R. China, Department of Cancer Molecular and Biology, Heilongjiang Academy of Medical Sciences, Harbin Medical University, Harbin, Heilongjiang 150040, P.R. China
Published online on: October 12, 2017 https://doi.org/10.3892/ol.2017.7178
Pages: 7398-7404
Copyright: © Zhi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The human ether‑a‑go‑go‑related potassium channel 1 (hERG1) is a component of the voltage‑gated Kv11.1 potassium channel, which has been recently indicated to have a crucial role in the tumorigenesis of multiple tumors, including pancreatic carcinoma. Pancreatic carcinoma is one of the most malignant human cancer types, which has an extremely poor prognosis. The present study demonstrated that the expression levels of hERG1 were markedly elevated in pancreatic cancer tissues and pancreatic cancer cell lines, and that the abnormal hERG1 expression was significantly associated with the proliferation and invasion ability of pancreatic cancer. Furthermore, hERG1 was identified to be a direct target of miR‑493, which is generally reduced in pancreatic cancer tissues and cell lines. These findings provide a novel insight into the regulatory mechanism of miR‑493/hERG1 in pancreatic cancer cell proliferation and invasion, which may aid the development of novel diagnostic and therapeutic strategies for pancreatic cancer in the future.

View Figures

View References

1	Moffitt RA, Marayati R, Flate EL, Volmar KE, Loeza SG, Hoadley KA, Rashid NU, Williams LA, Eaton SC, Chung AH, et al: Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat Genet. 47:1168–1178. 2015. View Article : Google Scholar : PubMed/NCBI
2	Zhou L, Yao LT, Liang ZY, Zhou WX, You L, Shao QQ, Huang S, Guo JC and Zhao YP: Nuclear translocation of fibroblast growth factor receptor 3 and its significance in pancreatic cancer. Int J Clin Exp Pathol. 8:14640–14648. 2015.PubMed/NCBI
3	Onyeaghala G, Nelson HH, Thyagarajan B, Linabery AM, Panoskaltsis-Mortari A, Gross M, Anderson KE and Prizment AE: Soluble MICA is elevated in pancreatic cancer: Results from a population based case-control study. Mol Carcinog. 56:2158–2164. 2017. View Article : Google Scholar : PubMed/NCBI
4	Yu Y, Liu L, Ma R, Gong H, Xu P and Wang C: MicroRNA-127 is aberrantly downregulated and acted as a functional tumor suppressor in human pancreatic cancer. Tumour Biol. 37:14249–14257. 2016. View Article : Google Scholar : PubMed/NCBI
5	Yang XP, Liu SL, Xu JF, Cao SG, Li Y and Zhou YB: Pancreatic stellate cells increase pancreatic cancer cells invasion through the hepatocyte growth factor/c-Met/survivin regulated by P53/P21. Exp Cell Res. 357:79–87. 2017. View Article : Google Scholar : PubMed/NCBI
6	Jixiang C, Shengchun D, Jianguo Q, Zhengfa M, Xin F, Xuqing W, Jianxin Z and Lei C: YEATS4 promotes the tumorigenesis of pancreatic cancer by activating beta-catenin/TCF signaling. Oncotarget. 8:25200–25210. 2017.PubMed/NCBI
7	Silverman BR and Shi J: Alterations of epigenetic regulators in pancreatic cancer and their clinical implications. Int J Mol Sci. 17:pii: E2138. 2016. View Article : Google Scholar : PubMed/NCBI
8	Mao Y, Shen J, Lu Y, Lin K, Wang H, Li Y, Chang P, Walker MG and Li D: RNA sequencing analyses reveal novel differentially expressed genes and pathways in pancreatic cancer. Oncotarget. 8:42537–42547. 2017.PubMed/NCBI
9	Wang J, Guo XJ, Ding YM and Jiang JX: miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer. World J Gastroenterol. 23:1594–1601. 2017. View Article : Google Scholar : PubMed/NCBI
10	Vandenberg JI, Perry MD, Perrin MJ, Mann SA, Ke Y and Hill AP: hERG K(+) channels: Structure, function, and clinical significance. Physiol Rev. 92:1393–1478. 2012. View Article : Google Scholar : PubMed/NCBI
11	Villoutreix BO and Taboureau O: Computational investigations of hERG channel blockers: New insights and current predictive models. Adv Drug Deliv Rev. 86:72–82. 2015. View Article : Google Scholar : PubMed/NCBI
12	Cubeddu LX: Drug-induced inhibition and trafficking disruption of ion channels: Pathogenesis of QT abnormalities and drug-induced fatal arrhythmias. Curr Cardiol Rev. 12:141–154. 2016. View Article : Google Scholar : PubMed/NCBI
13	Perez-Neut M, Haar L, Rao V, Santha S, Lansu K, Rana B, Jones WK and Gentile S: Activation of hERG3 channel stimulates autophagy and promotes cellular senescence in melanoma. Oncotarget. 7:21991–22004. 2016. View Article : Google Scholar : PubMed/NCBI
14	Becchetti A, Crescioli S, Zanieri F, Petroni G, Mercatelli R, Coppola S, Gasparoli L, D'Amico M, Pillozzi S, Crociani O, et al: The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression. Sci Signal. 10:pii: eaaf3236. 2017. View Article : Google Scholar : PubMed/NCBI
15	Arcangeli A and Becchetti A: hERG channels: From antitargets to novel targets for cancer therapy. Clin Cancer Res. 23:3–5. 2017. View Article : Google Scholar : PubMed/NCBI
16	Garzon R, Calin GA and Croce CM: MicroRNAs in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
17	Rachagani S, Macha MA, Heimann N, Seshacharyulu P, Haridas D, Chugh S and Batra SK: Clinical implications of miRNAs in the pathogenesis, diagnosis and therapy of pancreatic cancer. Adv Drug Deliv Rev. 81:16–33. 2015. View Article : Google Scholar : PubMed/NCBI
18	Sun B, Liu X, Gao Y, Li L and Dong Z: Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients. Br J Biomed Sci. 73:152–157. 2016. View Article : Google Scholar : PubMed/NCBI
19	Cai H, An Y, Chen X, Sun D, Chen T, Peng Y, Zhu F, Jiang Y and He X: Epigenetic inhibition of miR-663b by long non-coding RNA HOTAIR promotes pancreatic cancer cell proliferation via up-regulation of insulin-like growth factor 2. Oncotarget. 7:86857–86870. 2016.PubMed/NCBI
20	Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, et al: MicroRNA biomarkers in whole blood for detection of pancreatic cancer. JAMA. 311:392–404. 2014. View Article : Google Scholar : PubMed/NCBI
21	Kato K, Iwama H, Yamashita T, Kobayashi K, Fujihara S, Fujimori T, Kamada H, Kobara H and Masaki T: The anti-diabetic drug metformin inhibits pancreatic cancer cell proliferation in vitro and in vivo: Study of the microRNAs associated with the antitumor effect of metformin. Oncol Rep. 35:1582–1592. 2016. View Article : Google Scholar : PubMed/NCBI
22	Debska G, Kicinska A, Skalska J and Szewczyk A: Intracellular potassium and chloride channels: An update. Acta Biochim Pol. 48:137–144. 2001.PubMed/NCBI
23	Feng J, Yu J, Pan X, Li Z, Chen Z, Zhang W, Wang B, Yang L, Xu H, Zhang G and Xu Z: HERG1 functions as an oncogene in pancreatic cancer and is downregulated by miR-96. Oncotarget. 5:5832–5844. 2014. View Article : Google Scholar : PubMed/NCBI
24	Pengcheng S, Ziqi W, Luyao Y, Xiangwei Z, Liang L, Yuwei L, Lechen L and Wanhai X: MicroRNA-497 suppress renal cell carcinoma by targeting VEGFR-2 in ACHN cells. Biosci Rep. 37:pii: BSR20170270. 2017. View Article : Google Scholar : PubMed/NCBI
25	Zhang K, Zhang C, Liu L and Zhou J: A key role of microRNA-29b in suppression of osteosarcoma cell proliferation and migration via modulation of VEGF. Int J Clin Exp Pathol. 7:5701–5708. 2014.PubMed/NCBI